There is a lot of new information about the link between various malignancies and inflammatory bowel disease. Here: answers to 3 key questions.
Diet diaries and food frequency questionnaires are both effective tools to capture important patterns between food items and symptoms of IBD.
IDA is commonly seen in IBD as a result of iron malabsorption and, ironically, chronic blood loss through disrupted mucosal surfaces.
Patients with UC who also have celiac disease may be at higher risk for pancolitis as opposed to more limited forms of inflammatory bowel disease.
The mechanisms and effectiveness of probiotics in treatment of irritable bowel syndrome and inflammatory bowel disease are emerging.
New insights into how clinicians might approach treatment for patients with IBD highlighted the recent Crohn’s & Colitis Foundation’s Clinical & Research Conference.
The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.
New drugs are needed because a significant fraction of patients reach the end of the line with existing therapies.
All patients with IBD should receive aggressive ongoing assessment of their inflammatory state and its response to immunomodulators, anti-TNF drugs, and other agents.
A purely dichotomous understanding of whether to start treatment for patients who have IBD with anti-TNF agents is becoming an outdated view.